Schneyer Mark C. 4

What Happened

• Mark C. Schneyer, Chief Financial Officer of ACADIA Pharmaceuticals (ACAD), received two equity awards on March 6, 2026: 90,691 stock options and 26,382 restricted stock units (RSUs). Both awards were reported as derivative grants (transaction code A) with an acquisition price of $0.00 — i.e., awarded as compensation rather than purchased for cash. No immediate sale or cashless exercise was reported.

Key Details

• Transaction date: March 6, 2026; Form 4 filed March 10, 2026 (timely — within the two business‑day window).
• Awards: 90,691 stock options @ $0.00 (derivative), and 26,382 RSUs @ $0.00 (derivative).
• Shares owned after the transaction: not disclosed in the provided filing summary.
• Footnotes:
  • F1: Options vest 25% on March 6, 2027, then the remainder vests in 36 equal monthly installments thereafter.
  • F2: Each RSU is a contingent right to one share of common stock.
  • F3: RSUs vest in four equal annual installments beginning March 6, 2027.
• Transaction code meaning: A = Grant/Award. No tax‑withholding sale or 10b5‑1 plan noted in the summary.

Context

• These are equity compensation grants (options + RSUs). Options give the right to buy shares subject to the vesting schedule; RSUs convert to shares upon vesting. Because the grants were awarded (not bought or sold), they are generally part of executive compensation and do not by themselves signal a buy/sell decision by the insider.